

Food and Drug Administration Rockville MD 20857

MAR 2 6 1999

6434 '99 MAR 29 P1:31

Mr. Stephen J. Graham 10'Howard Court Woburn, Massachusetts 01801-5805

Dear Mr. Graham:

Thank you for your correspondence to Senator Edward M. Kennedy, regarding proposed new Food and Drug Administration (FDA or the Agency) regulations on statements made for dietary supplements concerning the effect of the product on the structure or function of the body. Senator Kennedy has asked us to respond directly to you.

FDA published this proposed rule in the <u>Federal Register</u> on April 29, 1998. The comment period closed on August 27, 1998; however, FDA extended the comment period until September 28, 1998. FDA invited written comments on the proposal from the public and industry. All comments received will be reviewed and considered by the Agency in developing the final rule.

Your comments have been forwarded to the docket for this issue. While the Agency is under no legal obligation to consider comments received after the comment period, we do try to accommodate all comments as time and resources permit.

Enclosed is information which may be of interest to you. We hope this information has been helpful.

Sincerely,

Sw Melinda K. Plaisier

Interim Associate Commissioner for Legislative Affairs

Timoth Lyngl

Enclosure
April 24, 1998 <u>HHS News</u> release

cc: Dockets Management Branch (Docket No. 98N-0044)

The Honorable Edward M. Kennedy United States Senator 2400A John F. Kennedy Federal Building Government Center Boston, Massachusetts 02203

C 22295 | ANS

4 LOG- 48P



Washington D.C. 20201 - 0001

MAR 2 1999

Executive Secretariat Office Food and Drug Administration Fishers Lane Room 1670 Rockville, Maryland 20857

Dear Ms. Clarke:

The attached correspondence was received by the Health Care Financing Administration. Since it appears that the attached correspondence can best be evaluated by your office, we are referring correspondence to you for your consideration and appropriate action.

Sincerely,

Mary Ann Troanovitch Jor Director

Division of Correspondence Control and Management

Enclosures

No 99-1517

United States Senate

MEMORANDUM

Respectfully referred to:

Ms. Diane Thomson Associate Comm. for Legislative Affairs FDA Dept. of HHS

My assistance has been requested concerning the attached correspondence.

I am forwarding this to you for your attention and consideration, and would appreciate your prompt reply directly to the constituent, with a copy sent to me at:

> 2400A John F. Kennedy Federal Bldg. Government Center Boston, Massachusetts 02203

Thank you for your attention and consideration.

Sincerely.

Edward M. Kennedy United States Senator

For additional information,

please contact _

_ at (617) 565-3170

No 99- 1517

CITIZENS PETITION

TO: FDA- Dockets Management Branch (HFA-305) 12420 Parklawn Drive, Room 1-23 Rockville, MD 20857

RE: [Docket No. 98N-0044] RIN 0910-AA59 Regulations on Statements Made for Dietary Supplements Concerning the Effect of the Product on the Structure or Function of the Body; Proposed Rule and Dietary Supplements: Comments on Report of the Commission on Dietary Supplement Labels; Notice

Please be advised that I vehemently oppose the proposed restrictions on the dissemination of medical information as it relates to dietary supplement health claims for the following reasons:

- 1. I need this information to determine what supplements I should take and which supplements I should avoid. Your restriction on the types of claims that can be made will adversely effect my health, and the health of the millions of Americans who rely on the dissemination of specific medical information relating to disease states in order to determine which dietary supplements to take.
- 2. Your proposed rules are in violation of the free speech provisions enumerated in the First Amendment to the United States Constitution.
- 3. Your proposed rules are contrary to a Supreme Court decision on June 28, 1993. The Commission on Dietary Supplement Labels (whose advice you were following when you drafted your proposed rule) defied the Supreme Court Decision of Daubert v. Merrill Dow. (I hereby put you on notice that the FDA is required to abide by Supreme Court decisions when proposing new regulations.)
- 4. In your proposed rule, you say that it would be illegal to suggest anything but drugs to reduce nausea associated with chemotherapy. This is arbitrary and capricious. What about nutrients such as ginger that have been shown to reduce nausea? What about coenzyme Q10 and vitamin E to reduce chemotherapy-induced cardiomyopathies, melatonin to reduce chemotherapy-induced immune system damage, and N-acetylcysteine to reduce chemotherapy induced liver damage? Are cancer patients to be denied this information?

Because your proposed rule is of questionable legality in view of the Daubert decision, and will cause many Americans to suffer and die, I hereby call for its immediate withdrawal.

Signed: Stiphen Graham	Date: F-5-98
Signed: Stephen Graham Address: 10 Howard Court	
City/State/Zip: Woburn MA 0/801-5805	

CC: To my U.S. representative and two senators